BioCryst Pharmaceuticals reported second quarter 2026 financial results with total net revenue of $218.3 million and ORLADEYO net revenue of $158.2 million. The company achieved a GAAP operating profit of $98.5 million and recognized $55.7 million in license revenue from its navenibart European rights agreement. BioCryst raised its full year 2026 total revenue guidance to $690–$715 million while maintaining ORLADEYO revenue guidance at $625–$645 million. Key operational updates include the commencement of ORLADEYO oral pellet shipments to pediatric patients on August 3, the completion of enrollment in the pivotal ALPHA-ORBIT navenibart study, and the appointment of David W. Jenkins as Chief Scientific Officer. The company operates in the biotechnology industry, focusing on developing and commercializing medicines for hereditary angioedema and other rare diseases.

BioCryst Pharmaceuticals is amending its June 29, 2026 filing to disclose estimated costs associated with discontinuing internal discovery programs and closing its Birmingham, Alabama Discovery Center of Excellence. The company estimates one-time expenses between $6.2 million and $7.5 million for employee termination benefits and severance, with approximately $5.3 million to $6.6 million expected in cash expenditures. Total facility closure costs remain unestimated as management analysis is ongoing. BioCryst Pharmaceuticals operates in the biotechnology industry, focusing on developing treatments for rare diseases.

BioCryst Pharmaceuticals, Inc. approved a plan to discontinue its internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama, as part of a strategic evolution to focus on rare disease pipeline. The implementation of the Plan is expected to be substantially complete by the end of 2026. The company is currently unable to estimate the total costs associated with the following: contract termination, lease termination, employee termination benefits, and severance. BioCryst Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes drugs for rare diseases.

On June 11, 2026, BioCryst Pharmaceuticals stockholders approved a proposal to amend and restate the Stock Incentive Plan, increasing the number of shares available for issuance by 7,000,000 shares. The company also elected directors Theresa M. Heggie, Amy E. McKee, and Jon P. Stonehouse, ratified Ernst & Young LLP as independent auditors, and passed a non-binding advisory vote on executive compensation. BioCryst Pharmaceuticals is a biopharmaceutical company that develops and commercializes medicines for rare diseases.